Aridis Pharmaceuticals
Los Gatos
About Aridis Pharmaceuticals
Aridis Pharmaceuticals discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The company is utilizing its proprietary ʎPEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome infection and to rapidly manufacture monoclonal antibodies (mAbs) for the therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $81.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2023)
- Ticker: nasdaq:ARDS
- Website: aridispharma.com
- Phone: 4089603822
Industries & Categories
Biotechnology, Content Discovery, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aridis-pharmaceuticals-142303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.